Hydroxyflutamide

Target genes for Hydroxyflutamide is obtained based on ToxCast assay component endpoints.
Chemical nameGene identifierToxCast assay component endpoint name
HydroxyflutamideCREB3ATG_CRE_CIS_up
HydroxyflutamideCSF1BSK_LPS_MCSF_down
HydroxyflutamideCYP1A2NVS_ADME_hCYP1A2
HydroxyflutamideCYP2C19NVS_ADME_hCYP2C19
HydroxyflutamideCYP19A1NVS_ADME_hCYP19A1
HydroxyflutamideESR1TOX21_ERa_BLA_Antagonist_ratio
HydroxyflutamideESR1ACEA_ER_80hr
HydroxyflutamideESR1TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2
HydroxyflutamideESR1TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2
HydroxyflutamideESR2TOX21_ERb_BLA_Antagonist_ratio
HydroxyflutamideESRRATOX21_ERR_Antagonist
HydroxyflutamideESRRATOX21_PGC_ERR_Antagonist
HydroxyflutamideIL6BSK_CASM3C_IL6_down
HydroxyflutamideCXCL10BSK_BE3C_IP10_down
HydroxyflutamideARACEA_AR_antagonist_80hr
HydroxyflutamideARNVS_NR_hAR
HydroxyflutamideAROT_AR_ARSRC1_0480
HydroxyflutamideARTOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide
HydroxyflutamideAROT_AR_ARSRC1_0960
HydroxyflutamideARTOX21_AR_BLA_Agonist_ratio
HydroxyflutamideARTOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881
HydroxyflutamideARTOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881
HydroxyflutamideARTOX21_AR_BLA_Antagonist_ratio
HydroxyflutamideARACEA_AR_agonist_80hr
HydroxyflutamideARTOX21_AR_LUC_MDAKB2_Agonist
HydroxyflutamideSMAD1ATG_BRE_CIS_up
HydroxyflutamideNFE2L2ATG_NRF2_ARE_CIS_up
HydroxyflutamideNFE2L2TOX21_ARE_BLA_agonist_ratio
HydroxyflutamidePGRNVS_NR_hPR
HydroxyflutamidePGRTOX21_PR_BLA_Antagonist_ratio
HydroxyflutamidePOU2F1ATG_Oct_MLP_CIS_up
HydroxyflutamidePPARAATG_PPRE_CIS_up
HydroxyflutamidePPARDATG_PPRE_CIS_up
HydroxyflutamidePPARGATG_PPARg_TRANS_up
HydroxyflutamidePPARGATG_PPRE_CIS_up
HydroxyflutamidePTGER2BSK_LPS_PGE2_down
HydroxyflutamideRXRBATG_RXRb_TRANS_up
HydroxyflutamideTHBDBSK_CASM3C_Thrombomodulin_down
HydroxyflutamideTP53TOX21_p53_BLA_p2_ratio
HydroxyflutamideNR1I2ATG_PXR_TRANS_up
HydroxyflutamideNR1I2ATG_PXRE_CIS_up

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.